A case for improving frail patient outcomes in multiple myeloma with phenotype‐driven personalized medicine
Open Access
- 16 February 2021
- journal article
- perspective
- Published by Wiley in Aging and Cancer
- Vol. 2 (1-2), 6-12
- https://doi.org/10.1002/aac2.12022
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- Immune Checkpoint Inhibitors in Older AdultsCurrent Oncology Reports, 2016
- Identification of precision treatment strategies for high risk multiple myeloma by ex vivo drug sensitivity testingClinical Lymphoma Myeloma and Leukemia, 2015
- Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group reportBlood, 2015
- The prevalence and outcomes of frailty in older cancer patients: a systematic reviewAnnals of Oncology, 2014
- Multiple myeloma in octogenarians: Clinical features and outcome in the novel agent eraEuropean Journal of Haematology, 2012
- Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN)Blood, 2011
- Multiple MyelomaThe New England Journal of Medicine, 2011
- The Frailty Syndrome: Definition and Natural HistoryClinics in Geriatric Medicine, 2011
- Recent major improvement in long-term survival of younger patients with multiple myelomaBlood, 2008
- Molecular Pathogenesis and a Consequent Classification of Multiple MyelomaJournal of Clinical Oncology, 2005